According to a new study, Remdesivir can significantly
reduce the risk of hospitalization for high-risk COVID-19 patients.
The
antiviral drug was tested on over 500 patients considered high risk due to
either their health conditions or age.
It was found that the drug reduced the risk of
hospitalization by 87% by day 28 and reduced the risk of dying by 81%.
Remdesivir
is currently approved for hospitalized patients 12 and over.